VORASIDENIB

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C14H13ClF6N6
Molecular Weight	414.737
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H](NC1=NC(=NC(N[C@H](C)C(F)(F)F)=N1)C2=CC=CC(Cl)=N2)C(F)(F)F

InChI

InChIKey=QCZAWDGAVJMPTA-RNFRBKRXSA-N

InChI=1S/C14H13ClF6N6/c1-6(13(16,17)18)22-11-25-10(8-4-3-5-9(15)24-8)26-12(27-11)23-7(2)14(19,20)21/h3-7H,1-2H3,(H2,22,23,25,26,27)/t6-,7-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C14H13ClF6N6
Molecular Weight	414.737
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/27355333 | https://clinicaltrials.gov/ct2/show/NCT02492737 | https://clinicaltrials.gov/ct2/show/NCT02481154

Vorasidenib (also known as AG 881) was developed as an isocitrate dehydrogenase (IDH) type 1 in the cytoplasm and type 2 in the mitochondria, with potential antineoplastic activity. It is known that IDH is an essential enzyme for cellular respiration in the tricarboxylic acid (TCA) cycle. Isocitrate dehydrogenases 1 and 2 (IDH1/2) are homodimeric enzymes that catalyze the conversion of isocitrate to α-ketoglutarate (α-KG) in the tricarboxylic acid cycle. Vorasidenib participated in phase I clinical trials in patients with advanced hematologic malignancies and in gliomas.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Isocitrate dehydrogenase [NADP], mitochondrial 5 Target ID: P48735 Gene ID: 3418.0 Gene Symbol: IDH2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27355333	Inhibitor 8297
Isocitrate dehydrogenase [NADP] cytoplasmic 3 Target ID: O75874 Gene ID: 3417.0 Gene Symbol: IDH1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/27355333	Inhibitor 8297

PubMed

Title	Date	PubMed
The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors.	2016	27292784
Targeting isocitrate dehydrogenase (IDH) in cancer.	2016 May	27355333
Inhibitors of Mutant Isocitrate Dehydrogenases 1 and 2 (mIDH1/2): An Update and Perspective.	2018 Oct 25	29847930
Crystal structures of pan-IDH inhibitor AG-881 in complex with mutant human IDH1 and IDH2.	2018 Sep 18	30131249

Sample Use Guides

In Vivo Use Guide

oral doses of AG-881 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Sat Dec 16 02:16:22 GMT 2023` Edited by `admin` on `Sat Dec 16 02:16:22 GMT 2023`
Record UNII	789Q85GA8P
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VORASIDENIB

Official Name

English

vorasidenib [INN]

Common Name

English

AG-881

Code

English

Vorasidenib [WHO-DD]

Common Name

English

VORASIDENIB [USAN]

Common Name

English

1,3,5-TRIAZINE-2,4-DIAMINE, 6-(6-CHLORO-2-PYRIDINYL)-N2,N4-BIS((1R)-2,2,2-TRIFLUORO-1-METHYLETHYL)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C137826